

ChemoCentryx Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 12-Dec-2012

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 12

 Phase 2 Clinical..... 13

 Phase 1 Clinical..... 29

 Discovery..... 30

[Return to Table of Contents](#)

ChemoCentryx Inc

COMPANY OVERVIEW

Company Name	ChemoCentryx Inc
Parent Company Name	ChemoCentryx Inc
Website	http://www.chemocentryx.com/
Country	US
Number of Drugs in Active Development	9
Number of Inactive Drugs	12
Number of Patents as Owner	53
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Autoimmune disease, Inflammatory disease, Rheumatoid arthritis, Inflammatory bowel disease, Restenosis, Multiple sclerosis, Cancer, Vasculitis, Atopic dermatitis, Metabolic disorder, Non-insulin dependent diabetes
Key Target-based Actions	CCR1 chemokine antagonist, CCR2 chemokine antagonist, CCR9 chemokine antagonist, CXCR7 chemokine antagonist, Complement C5a receptor antagonist, Chemokine receptor-like 1 antagonist, CCR4 chemokine antagonist, CD11b antagonist, CXCR3 chemokine antagonist, CXCR4 chemokine antagonist, CXCR6 chemokine antagonist
Key Technologies	Small molecule therapeutic, Oral formulation, Capsule formulation, Analytical method, Antibody, Diagnostic method, Drug screening, Fluorescence, Imaging, Immunodetection, Monoclonal antibody

COMPANY PROFILE

SUMMARY

ChemoCentryx is a private technology and drug discovery company located in the US, and is committed to the R&D of orally-delivered small molecule therapeutics for infectious and inflammatory diseases based on the biology of chemokines and chemokine receptors.

Initial funding for the company was provided through a Research, Collaborative and Investment Agreement with Techne Corp and their subsidiary, R&D Systems. Major non-dilutive support has also been obtained through the Defense Advanced Research Program through two separate grants.

LICENSING AGREEMENTS

In August 2006, GlaxoSmithKline (GSK) and ChemoCentryx joined forces to develop drugs targeting chemokine and chemoattractant receptors for the treatment of inflammatory disorders. The deal included CCX-282, for which ChemoCentryx retained an option to codevelop and comarket to US specialists. ChemoCentryx would receive \$63.5 million in cash and series D financing upfront, research funding, up to \$1.5 billion in milestone payments and double-digit royalties.

EARLY R&D

By April 2008, the company was evaluating compounds targeting chemokine receptors such as CCR5, CCR10, CCR12 and CXCR2 for preclinical development.

FINANCIAL

In February 2012, the company priced an IPO of 4.5 million shares at \$10.00 per share, and underwriters were granted a 30-day option to purchase an additional 0.675 million shares, to cover overallotments. The shares would begin trading on the NASDAQ Global Market under 'CCXI' symbol from February 08, 2012. At that time, the offering was expected to close on February 13, 2012; the offering was completed later in February 2012; at that time, the company raised \$63.7 million gross proceeds from the private placement. Net proceeds raised were \$57 million.

[Return to Table of Contents](#)



In June 2006, ChemoCentryx completed a series C financing, raising \$17.7 million.

In June 2004, ChemoCentryx announced that it had closed a private financing round raising gross proceeds of \$33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round.

R&D GRANTS

In October 2003, the NIAID awarded ChemoCentryx a \$14 million grant to develop first-in-class immune modulatory agents targeting chemokine receptors, for the prevention and treatment of infectious diseases that may be caused by biological warfare pathogens.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Inflammatory disease	6	7	13
Immune disorder	6	6	12
Gastrointestinal disease	2	3	5
Neoplasm	1	3	4
Dermatological disease	1	2	3
Neurological disease	1	2	3
Metabolic disorder	2	1	3
Cardiovascular disease	2	1	3
Musculoskeletal disease	1	1	2
Infectious disease	0	1	1
Respiratory disease	1	0	1
Hematological disease	0	1	1
Endocrine disease	1	0	1
Genitourinary disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	3
Phase 1 Clinical	1
Discovery	5
Discontinued	2
No Development Reported	9

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	1	0	0	0	2
Drug - Commercialization License	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Inflammatory disease	1	13
Immune disorder	0	10
Gastrointestinal disease	1	9
Metabolic disorder	1	4
Endocrine disease	1	3
Musculoskeletal disease	0	3
Cardiovascular disease	1	3
Neurological disease	0	2
Genitourinary disease	2	2

[Return to Table of Contents](#)



Trials by Phase

Phase	Ongoing	All
Phase 3	0	1
Phase 2	3	8
Phase 1	0	8

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Immune disorder	37	0	37
Neoplasm	30	0	30
Ocular disease	3	0	3
Metabolic disorder	14	0	14
Neurological disease	24	0	24
Prophylaxis	2	0	2
Degeneration	8	0	8
Andrology	1	0	1
Cardiovascular disease	24	0	24
Endocrine disease	12	0	12
Genitourinary disease	4	0	4
Dermatological disease	23	0	23
Otorhinolaryngological disease	1	0	1
Gastrointestinal disease	22	0	22
Hematological disease	7	0	7
Musculoskeletal disease	29	0	29

[Return to Table of Contents](#)



Nutritional disorder	5	0	5
Respiratory disease	23	0	23
Infectious disease	24	0	24
Injury	2	0	2
Inflammatory disease	44	0	44
Gynecology and obstetrics	2	0	2

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

CCX-140

CCX-140 SNAPSHOT

Drug Name	CCX-140
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Diabetic nephropathy;Multiple sclerosis;Restenosis;Non-insulin dependent diabetes;End stage renal disease
Target-based Actions	CCR2 chemokine antagonist
Other Actions	Hypoglycemic agent;Anti-inflammatory
Technologies	Oral formulation;Capsule formulation;Small molecule therapeutic
Last Change Date	28-Nov-2012

CCX-140 DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is developing CCX-140 (CCX-140-B), a small-molecule CCR2 receptor antagonist, for the potential oral treatment of type 2 diabetes, kidney disease and inflammatory conditions such as vascular restenosis and multiple sclerosis,. In January 2010, a phase II trial for type 2 diabetes was initiated ; by January 2011, the trial had been completed. By May 2008, a phase I single-dose trial had begun for vascular restenosis and multiple sclerosis. It was to be followed by a phase I multiple-dose trial then safety and proof-of-concept trials in patients with inflammatory or metabolic diseases ; by March 2010, phase I trials had been completed. By July 2011, the drug was listed as being in phase II development for chronic kidney disease. In March 2012, the company planned to launch CCX-140 in North America. In October 2011, a phase II trial for diabetic nephropathy was initiated ; in October 2012, the company expected to report data from two phase II studies in 2013. In December 2011, the company planned to initiate phase III clinical development on completion of the phase II trial in diabetic nephropathy. In October 2012, the company was seeking to outlicense the drug to Ex-North American partner.

CCX-140 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Diabetic nephropathy	Belgium	Phase 2 Clinical	11-Oct-2011

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Diabetic nephropathy	Hungary	Phase 2 Clinical	11-Oct-2011
ChemoCentryx Inc	End stage renal disease	US	Phase 2 Clinical	23-Jun-2011
ChemoCentryx Inc	Non-insulin dependent diabetes	Australia	Phase 2 Clinical	29-Jan-2010
ChemoCentryx Inc	Non-insulin dependent diabetes	Europe	Phase 2 Clinical	29-Jan-2010
ChemoCentryx Inc	Non-insulin dependent diabetes	New Zealand	Phase 2 Clinical	29-Jan-2010
ChemoCentryx Inc	Multiple sclerosis	Switzerland	Phase 1 Clinical	13-May-2008
ChemoCentryx Inc	Restenosis	Switzerland	Phase 1 Clinical	13-May-2008

CCX-140 DRUG NAMES

Names	Type
CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease), ChemoCentryx CCX-140	Research Code
CCX-140-B	Research Code
CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease/chronic kidney disease), ChemoCentryx CCX-417	Analogue

CCX-140 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Non-insulin dependent diabetes											
0	0	0	0	1	2	0	1	0	0	1	3
Multiple sclerosis											
0	0	0	0	0	0	0	2	0	0	0	2
Metabolic disorder											
0	0	0	0	0	0	0	2	0	0	0	2
Inflammatory disease											
0	0	0	0	0	0	0	2	0	0	0	2

[Return to Table of Contents](#)

Albuminuria											
0	0	0	0	1	1	0	0	0	0	1	1
Diabetic nephropathy											
0	0	0	0	1	1	0	0	0	0	1	1
Restenosis											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	2	3	0	2	0	0	2	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
ChemoCentryx Inc	1	0	1
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

[Return to Table of Contents](#)

CCX-354

CCX-354 SNAPSHOT

Drug Name	CCX-354
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	GlaxoSmithKline plc;ChemoCentryx Inc
Inactive Companies	Forest Laboratories Inc
Highest Status	Phase 2 Clinical
Active Indications	Rheumatoid arthritis
Target-based Actions	CCR1 chemokine antagonist
Other Actions	Anti-inflammatory;Leukocyte infiltration inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	14-Jun-2012

CCX-354 DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx and GlaxoSmithKline (GSK) are developing CCX-354 (CCX0354-C, 2941266, GSK-2941266), a small-molecule CCR1 chemokine antagonist, for the potential oral treatment of inflammatory diseases such as rheumatoid arthritis (RA),. In December 2009, a phase I/II trial for RA was initiated ; by October 2011, the trial had been completed.

This program possibly stemmed from ChemoCentryx CCX-105 series of anti-inflammatory agents.

Forest Laboratories was previously collaborating with ChemoCentryx on this program ; however, by December 2005, the collaboration had been terminated, and Forest was no longer involved.


CCX-354 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Rheumatoid arthritis	Belgium	Phase 2 Clinical	07-Dec-2009
GlaxoSmithKline plc	Rheumatoid arthritis	Belgium	Phase 2 Clinical	07-Dec-2009
Forest Laboratories Inc	Rheumatoid arthritis	US	Discontinued	31-Dec-2005

[Return to Table of Contents](#)

CCX-354 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	5
	

CCX-354 DRUG NAMES

Names	Type
CCR1 antagonists (autoimmune diseases), Forest Laboratories/ChemoCentryx	
CCX-354	Research Code
CCR1 antagonist (rheumatoid arthritis), ChemoCentryx/GlaxoSmithKline	
CCX-354-C	Research Code
2941266	Research Code
GSK-2941266	Research Code

CCX-354 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Rheumatoid arthritis											
0	0	0	0	0	1	0	2	0	0	0	3
Inflammatory disease											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	2	0	0	0	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

CCX-354 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
ChemoCentryx Inc	1	1	0	0	2
Forest Laboratories Inc	0	0	0	1	1
GlaxoSmithKline plc	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	1	2

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
ChemoCentryx Inc	3	0	3
GlaxoSmithKline plc	1	0	1

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	2
New use	1

[Return to Table of Contents](#)

CCX-168

CCX-168 SNAPSHOT

Drug Name	CCX-168
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	GlaxoSmithKline plc;ChemoCentryx Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Autoimmune disease;Inflammatory disease;Vasculitis
Target-based Actions	Complement C5a receptor antagonist;CD11b antagonist
Other Actions	Anti-inflammatory
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	15-Jun-2012

CCX-168 DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx, subject to an alliance with GlaxoSmithKline (GSK), is developing CCX-168, the lead in a series of small molecule, orally bioavailable C5a receptor antagonists, for the potential treatment of autoimmune and inflammatory diseases, such as age-related macular degeneration, particular types of vasculitis, glomerulonephritis, rheumatoid arthritis and systemic lupus erythematosus,. In August 2011, a phase II renal vasculitis trial was initiated ; in March 2012, the company expected to complete the patient enrollment by the end of 2012.

CCX-168 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Vasculitis	EU	Phase 2 Clinical	27-Aug-2011
GlaxoSmithKline plc	Vasculitis	EU	Phase 2 Clinical	27-Aug-2011
ChemoCentryx Inc	Autoimmune disease	Norway	Phase 1 Clinical	28-Jan-2009
ChemoCentryx Inc	Inflammatory disease	Norway	Phase 1 Clinical	28-Jan-2009
GlaxoSmithKline plc	Autoimmune disease	Norway	Phase 1 Clinical	28-Jan-2009
GlaxoSmithKline plc	Inflammatory disease	Norway	Phase 1 Clinical	28-Jan-2009

[Return to Table of Contents](#)

CCX-168 DRUG NAMES

Names	Type
C5a receptor modulators (inflammatory disease), ChemoCentryx/GSK	
CCX-168	Research Code

CCX-168 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Vasculitis											
0	0	0	0	1	1	0	1	0	0	1	2

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	1	0	0	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

CCX-168 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
ChemoCentryx Inc	1	0	0	0	1
GlaxoSmithKline plc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
ChemoCentryx Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

[Return to Table of Contents](#)

CCX-872

CCX-872 SNAPSHOT

Drug Name	CCX-872
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Metabolic disorder
Target-based Actions	CCR2 chemokine antagonist
Other Actions	
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	28-Nov-2012

CCX-872 DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is developing CCX-872, a next-generation CCR2 antagonist, for the potential oral treatment of metabolic diseases, including diabetic neuropathy. In November 2012, a phase I trial was initiated. In October 2012, the company was seeking to outlicense the drug to Ex-North American partner.

CCX-872 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Metabolic disorder	US	Phase 1 Clinical	27-Nov-2012

CCX-872 DRUG NAMES

Names	Type
CCX-872	Research Code

[Return to Table of Contents](#)



CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx

CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx SNAPSHOT

Drug Name	CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Autoimmune disease;Lung disease;Atopic dermatitis
Target-based Actions	CCR4 chemokine antagonist
Other Actions	Dermatological agent;Anti-inflammatory
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	13-Sep-2012

CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is investigating a small molecule CCR4 chemokine antagonist, for the potential oral treatment of pulmonary diseases, autoimmune diseases and atopic dermatitis. In June 2011, the drug was listed as being in preclinical development ; in September 2012, this was still the case.

CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Atopic dermatitis	US	Discovery	23-Jun-2011
ChemoCentryx Inc	Autoimmune disease	US	Discovery	12-Sep-2012
ChemoCentryx Inc	Lung disease	US	Discovery	23-Jun-2011

[Return to Table of Contents](#)



CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx
DRUG NAMES

Names	Type
CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis), ChemoCentryx	
CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx	

[Return to Table of Contents](#)

CXCR7 antagonists, ChemoCentryx

CXCR7 antagonists, ChemoCentryx SNAPSHOT

Drug Name	CXCR7 antagonists, ChemoCentryx
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease;Cancer;Glioblastoma
Target-based Actions	CXCR7 chemokine antagonist
Other Actions	Angiogenesis inhibitor;Anticancer;Anti-inflammatory
Technologies	Small molecule therapeutic;Oral formulation
Last Change Date	12-Sep-2012

CXCR7 antagonists, ChemoCentryx DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is investigating CXCR7 antagonists, including orally administered CCX-754 for the potential treatment of cancer, CCX-733 for inflammation and CCX-662, for glioblastoma and other cancers . In September 2010, the program was listed on the company's pipeline as being in preclinical studies. In June 2011, CCX-662 was listed as being in preclinical development . In June 2012, preclinical data were presented. In September 2012, the company planned to initiate phase I development for CCX-662 in the first half of 2013. In October 2011, the company was seeking to outlicense CCX-662.

CXCR7 antagonists, ChemoCentryx DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Cancer	US	Discovery	24-Feb-2005
ChemoCentryx Inc	Glioblastoma	US	Discovery	13-Dec-2010
ChemoCentryx Inc	Inflammatory disease	US	Discovery	07-Jul-2009

[Return to Table of Contents](#)



CXCR7 antagonists, ChemoCentryx DRUG NAMES

Names	Type
CXCR7 antagonists, ChemoCentryx	
CCX-754	Research Code
CCX-733	Research Code
CCX-662	Research Code

[Return to Table of Contents](#)

CCR1 antagonists (autoimmune diseases), ChemoCentryx

CCR1 antagonists (autoimmune diseases), ChemoCentryx SNAPSHOT

Drug Name	CCR1 antagonists (autoimmune diseases), ChemoCentryx
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Autoimmune disease
Target-based Actions	CCR1 chemokine antagonist
Other Actions	Chemotaxis inhibitor
Technologies	Small molecule therapeutic
Last Change Date	04-Jun-2012

CCR1 antagonists (autoimmune diseases), ChemoCentryx DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is investigating CCR1 antagonists, for the potential treatment of autoimmune diseases, including rheumatoid arthritis. In May 2012, preclinical data were presented.


CCR1 antagonists (autoimmune diseases), ChemoCentryx DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Autoimmune disease	US	Discovery	21-May-2012

CCR1 antagonists (autoimmune diseases), ChemoCentryx CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	4
	

CCR1 antagonists (autoimmune diseases), ChemoCentryx DRUG NAMES

Names	Type
CCR1 antagonists (autoimmune diseases), ChemoCentryx	

[Return to Table of Contents](#)

CCX-507

CCX-507 SNAPSHOT

Drug Name	CCX-507
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory bowel disease
Target-based Actions	CCR9 chemokine antagonist
Other Actions	Anti-inflammatory
Technologies	Small molecule therapeutic
Last Change Date	28-May-2012

CCX-507 DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is investigating CCX-507, a next-generation CCR9 antagonist, for the potential treatment of inflammatory bowel disease. In April 2012, the drug was in preclinical development. In March 2012, the company expected to initiate phase I trials either for CCX-872 or CCX-507.

CCX-507 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Inflammatory bowel disease	US	Discovery	31-Dec-2011

CCX-507 DRUG NAMES

Names	Type
CCX-507	Research Code

[Return to Table of Contents](#)



CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx

CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx SNAPSHOT

Drug Name	CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx
Key Synonyms	
Originator Company	ChemoCentryx Inc
Active Companies	ChemoCentryx Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Autoimmune disease;Inflammatory disease
Target-based Actions	CXCR6 chemokine antagonist
Other Actions	Anti-inflammatory
Technologies	Small molecule therapeutic;Oral formulation
Last Change Date	13-Sep-2012

CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx DEVELOPMENT PROFILE

SUMMARY

ChemoCentryx is investigating CXCR6 antagonist, for the potential oral treatment of autoimmune disease and inflammation, including lung inflammation. In June 2011, the drug was listed as being in preclinical development ; in September 2012, this was still the case.

CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
ChemoCentryx Inc	Autoimmune disease	US	Discovery	09-Dec-2011
ChemoCentryx Inc	Inflammatory disease	US	Discovery	23-Jun-2011

CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx DRUG NAMES

Names	Type
CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

